# COVID-19 Vaccine Hesitancy: A Cross-Sectional Study of Visible Minority Canadian Communities

## TL;DR

This study explores vaccine hesitancy among visible minority communities in Canada, identifying regional differences in vaccine choices, side effects, and trust in information sources.

## Contribution

The study provides region-specific insights into vaccine hesitancy among visible minorities in Canada using a weighted survey analysis.

## Key findings

- Pfizer was most commonly administered in Ontario, the Prairies, British Columbia, and Quebec.
- Pain at the injection site was the most common side effect reported across multiple regions.
- Healthcare professionals and government sources were the most trusted information sources, with regional variations in trust levels.

## Abstract

The World Health Organization (WHO) defines vaccine hesitancy as reluctance or refusal to vaccinate despite availability. Contributing factors in visible minority populations include vaccine safety, effectiveness, mistrust, socioeconomic characteristics, vaccine development, information circulation, knowledge, perceived risk of COVID-19, and perceived benefit. Objectives: This study aimed to examine vaccine hesitancy in visible minority populations across Canadian regions. Methods: A survey was conducted among visible minority populations in Canadian regions, using 21 questions from the available literature via the Delphi method. The Canadian Hub for Applied and Social Research (CHASR) administered the survey to individuals 18 years or older who resided in Canada at the time of the survey and identified as visible minorities such as Asian, Black, and Latin American. After recruiting 511 participants, data analysis used Chi-square tests of association and 95% confidence intervals (CIs) to identify regional differences in vaccine choices, side effects, information sources, and reasons for vaccination. A weighted analysis extended the results to represent the visible minorities across provinces. Results: Higher rates of Pfizer were administered to participants in Ontario (73%), the Prairies (72%), British Columbia (71%), and Quebec (70%). British Columbia had the highest Moderna rate (59%). The most common side effect was pain at the injection site in Quebec (62%), Ontario (62%), BC (62%), and in the Atlantic (61%). Healthcare professionals and government sources were the most trusted information sources, with healthcare professionals trusted particularly in the Prairies (70%) and government sources similarly trusted in Quebec (65%) and Ontario (65%). In the Atlantic, 86% of refusals were due to side effects and 69% were due to prior negative vaccine experiences. Conclusions: Leveraging healthcare professionals’ trust, community engagement, and flexible policies can help policymakers improve pandemic preparedness and boost vaccine acceptance.